AVE 8112
Alternative Names: AVE 8112A; AVE8112Latest Information Update: 05 Nov 2015
Price :
$50 *
At a glance
- Originator sanofi-aventis
- Developer Sanofi; sanofi-aventis; The Michael J. Fox Foundation for Parkinson's Research
- Class Antidementias
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Parkinson's disease
Most Recent Events
- 02 Oct 2015 Discontinued - Phase-I for Parkinson's disease (Adjunctive treatment) in USA (PO)
- 01 Jan 2013 Phase-I clinical trials in Parkinson's disease (adjunctive treatment) in USA (PO)
- 19 Apr 2012 Sanofi enters into a collaboration with the Michael J. Fox Foundation for a clinical trial in Parkinson's disease